The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with metronidazole for patients 18 years and older who have limited or no alternative options for the ...
艾伯维(AbbVie)公司今日(2月8日)宣布,美国FDA已批准该公司与辉瑞(Pfizer)联合开发的Emblaveo(aztreonam和avibactam)上市,与甲硝唑联合使用 ...
AbbVie announced that the US Food and Drug Administration (FDA) has approved Emblaveo (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/ß-lactamase inhibitor ...
The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative ...
NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI ...
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo (aztreonam-avibactam) to treat complicated intra-abdominal infections, including those ...
艾伯维公司(ABBV)股价创下重要里程碑,达到历史最高点207.34美元。这家市值3,650亿美元、年收入超过560亿美元的制药巨头继续展示其市场主导地位。根据 InvestingPro 分析,该股票的相对强弱指数(RSI)显示处于超买区域,提示投资者需谨慎选择入场时机。这一新高反映了过去一年的强劲表现,该制药巨头股价增长了17.45%。公司的盘坚地位进一步得到巩固,这得益于其连续12年提高股息的 ...
NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果